Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01783561 · ClinicalTrials.gov registry record · Phase 4

Early Versus Routine Caffeine Administration in Extremely Preterm Neonates

A Phase 4 study of Caffeine, sponsored by Sharp HealthCare.

Completed
Registry status
Phase 4
Development phase
21
Enrollment target
1
Study location

NCT01783561 is a Phase 4 study of Caffeine that has completed, run by Sharp HealthCare. The registered enrollment target is 21 participants, below the 72-participant average among 6 other Caffeine trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01783561, a Phase 4 study of Caffeine, has completed, sponsored by Sharp HealthCare.

COMPLETED
Registry status
Phase 4
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Premature infants are at risk of having pauses in breathing, or apneas, due to their immaturity. Premature infants are routinely given caffeine, a respiratory stimulant, on the first day of life to prevent apneas. However, if they continue to have apneas, they may require a breathing tube to be placed in the trachea. There are risks to having a breathing tube, so it would be beneficial to avoid it if possible. If caffeine is given earlier, it may decrease the need for a breathing tube. Some studies also suggest that caffeine may also improve heart function which may prevent low blood pressure if given early.

Conditions Studied

Interventions

  • DRUG Caffeine

Study Locations (1)

California

  • Sharp Memorial Hospital - San Diego

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2013-10
Est. Completion 2014-05
Phase Phase 4

Sponsor

Sharp HealthCare

32 total trials

What the Registry Record Tells You About NCT01783561

The ClinicalTrials.gov registry entry for NCT01783561 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 6 other Caffeine trials with a reported enrollment target (71% lower). The listed sponsor is Sharp HealthCare, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Caffeine appearing as the primary indexed condition, and to 1 intervention - of which Caffeine is the first listed.

NCT01783561 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01783561 about?

NCT01783561 is a clinical study titled "Early Versus Routine Caffeine Administration in Extremely Preterm Neonates". Premature infants are at risk of having pauses in breathing, or apneas, due to their immaturity. Premature infants are routinely given caffeine, a respiratory stimulant, on the first day of life to prevent apneas. However, if they continue to have apneas, they may require a breathing tube to be plac...

What is the current status of trial NCT01783561?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2013-10. Estimated completion is 2014-05.

What conditions does trial NCT01783561 study?

This clinical trial studies the following conditions: Caffeine.

What interventions are being tested in trial NCT01783561?

The interventions under investigation include: Caffeine (DRUG).

Who is sponsoring clinical trial NCT01783561?

This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01783561 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Caffeine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.